Accepted Manuscript

The Combination of MK-5172, Peginterferon, and Ribavirin is Effective in Treatment-Naive Patients with Hepatitis C Virus Genotype 1 Infection Without Cirrhosis

Michael P. Manns, John M. Vierling, Bruce R. Bacon, Savino Bruno, Oren Shibolet, Yaacov Baruch, Patrick Marcellin, Luzelena Caro, Anita YM. Howe, Christine Fandozzi, Jacqueline Gress, Christopher L. Gilbert, Peter M. Shaw, Michael P. Cooreman, Michael N. Robertson, Peggy Hwang, Frank J. Dutko, Janice Wahl, Niloufar Mobashery

 PII:
 S0016-5085(14)00460-0

 DOI:
 10.1053/j.gastro.2014.04.006


 Reference:
 YGAST 59080

To appear in: *Gastroenterology* Accepted Date: 6 April 2014

Please cite this article as: Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N, The Combination of MK-5172, Peginterferon, and Ribavirin is Effective in Treatment-Naive Patients with Hepatitis C Virus Genotype 1 Infection Without Cirrhosis, *Gastroenterology* (2014), doi: 10.1053/j.gastro.2014.04.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in Gastroenterology are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.



The Combination of MK-5172, Peginterferon, and Ribavirin is Effective in Treatment-Naive Patients with Hepatitis C Virus Genotype 1 Infection Without Cirrhosis

Michael P Manns^{1*}, John M Vierling², Bruce R Bacon³, Savino Bruno⁴, Oren Shibolet⁵, Yaacov Baruch⁶, Patrick Marcellin⁷, Luzelena Caro⁸, Anita YM Howe⁸, Christine Fandozzi⁸, Jacqueline Gress⁸, Christopher L Gilbert⁸, Peter M Shaw⁸, Michael P Cooreman^{8†}, Michael N Robertson⁸, Peggy Hwang⁸, Frank J Dutko⁸, Janice Wahl⁸, Niloufar Mobashery⁸

¹Hannover Medical School, Hannover, Germany, ²Baylor College of Medicine, Houston, Texas, USA, ³Saint Louis University, Saint Louis, Missouri, USA, ⁴A.O. Fatebenefratelli e Oftalmico, Milan, Italy, ⁵Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center, Tel-Aviv, Israel, ⁶Liver Unit, Rambam Health Care Campus, Haifa, Israel, ⁷University Paris-Diderot, Clichy, France, ⁸Merck & Co., Inc., Whitehouse Station, New Jersey, USA

[†] Former employee of Merck & Co., Inc., Whitehouse Station, New Jersey, USA

Short Title-Efficacy and safety of MK-5172+PR in G1 HCV patients (44 characters; Limit: 45 characters) *Grant Support*- The study was sponsored and funded by Merck & Co., Inc., Whitehouse Station, NJ, USA. *Abbreviations* – hepatitis C virus, HCV; protease inhibitor, PI; peginterferon/ribavirin, PR; genotype 1, G1; response-guided therapy, RGT; treatment week, TW; boceprevir, BOC; sustained virologic response at 24 weeks after end of treatment, SVR24; nonstructural protein 3 and 4A of hepatitis C virus, NS3/4A; resistance-associated variants, RAV; human immunodeficiency virus type 1, HIV-1; international units, IU; HCV-RNA target not detected, TND; complete early virologic response, cEVR; alanine aminotransferase, ALT; aspartate aminotransferase, AST; upper limit of normal, ULN; human leukocyte antigen, HLA; absorption, distribution, metabolism and excretion, ADME; likelihood ratio test, LRT; multidrug resistanceassociated protein 2, MRP2; rapid virologic response, RVR; serious adverse event, SAE; direct acting Download English Version:

https://daneshyari.com/en/article/6095231

Download Persian Version:

https://daneshyari.com/article/6095231

Daneshyari.com